http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 18 Jun 2026 08:05:05 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Corporate+News/Gandeeva+and+Zymeworks+partner+on+cryo-EM+antibody+structure+work/26663182.html <p>Gandeeva Therapeutics, Inc. and Zymeworks Inc. (Nasdaq: ZYME), both based in Vancouver, Canada, have formed a partnership to use cryo-electron microscopy (cryo-EM) to map antibody-antigen binding interfaces in support of antibody drug discovery, according to a press release.</p><p>The collaboration produced a structural result that the companies say addresses a known technical limitation. While cryo-EM is routinely used to study antibody complexes with well-folded antigens, determining structures involving small and flexible antigens has remained difficult. Gandeeva scientists determined the structure of a small antigen — under 20 kilodaltons — bound to the Fab fragment of an antibody developed at Zymeworks, resolving http://www.streetinsider.com/Corporate+News/Gandeeva+and+Zymeworks+partner+on+cryo-EM+antibody+structure+work/26663182.html Thu, 18 Jun 2026 08:05:05 -0400 ZYME http://www.streetinsider.com/Press+Releases/Gandeeva+and+Zymeworks+Use+Cryo-EM+to+Accelerate+Antibody+Drug+Discovery/26663076.html <div class="xn-content"> <p><i><location value="LU/ca.bc.vancvr" idsrc="xmltag.org" >Vancouver</location>-based biotech companies <span value="ACORN:5021694305" idsrc="xmltag.org" >Gandeeva Therapeutics</span> and <span value="NASDAQ-NMS:ZYME" idsrc="xmltag.org" >Zymeworks</span> have partnered to generate cryo-EM–based structural data to augment antibody drug discovery.</i></p><p><span class="legendSpanClass"><location value="LU/ca.bc.vancvr" idsrc="xmltag.org" >VANCOUVER, BC</location></span>, <span class="legendSpanClass"><chron>June 18, 2026</chron></span> /PRNewswire/ - <span value="ACORN:5021694305" idsrc="xmltag.org" >Gandeeva Therapeutics, Inc.</span>, a biotech at the forefront of cryo-electron microscopy (cryo-EM)<i>–</i>driven drug design, and <span value="NASDAQ-NMS:ZYME" idsrc="xmltag.org" >Zymeworks Inc.</span> (Nasdaq: ZYME), a global biotechnology company, have partnered to visualize structures of antibody-antigen interfaces at high resolution.</p><p>While cryo-EM is now used routinely to determine structures of antibody complexes formed with compact and well-folded antigens, mapping antibody epitope footprints http://www.streetinsider.com/Press+Releases/Gandeeva+and+Zymeworks+Use+Cryo-EM+to+Accelerate+Antibody+Drug+Discovery/26663076.html Thu, 18 Jun 2026 08:00:00 -0400 A.50216943 O.02586910 O.56599086 ZYME http://www.streetinsider.com/Press+Releases/Gandeeva+and+Zymeworks+Use+Cryo-EM+to+Accelerate+Antibody+Drug+Discovery/26663076.html <div class="xn-content"> <p><i><location value="LU/ca.bc.vancvr" idsrc="xmltag.org" >Vancouver</location>-based biotech companies <span value="ACORN:5021694305" idsrc="xmltag.org" >Gandeeva Therapeutics</span> and <span value="NASDAQ-NMS:ZYME" idsrc="xmltag.org" >Zymeworks</span> have partnered to generate cryo-EM–based structural data to augment antibody drug discovery.</i></p><p><span class="legendSpanClass"><location value="LU/ca.bc.vancvr" idsrc="xmltag.org" >VANCOUVER, BC</location></span>, <span class="legendSpanClass"><chron>June 18, 2026</chron></span> /PRNewswire/ - <span value="ACORN:5021694305" idsrc="xmltag.org" >Gandeeva Therapeutics, Inc.</span>, a biotech at the forefront of cryo-electron microscopy (cryo-EM)<i>–</i>driven drug design, and <span value="NASDAQ-NMS:ZYME" idsrc="xmltag.org" >Zymeworks Inc.</span> (Nasdaq: ZYME), a global biotechnology company, have partnered to visualize structures of antibody-antigen interfaces at high resolution.</p><p>While cryo-EM is now used routinely to determine structures of antibody complexes formed with compact and well-folded antigens, mapping antibody epitope footprints http://www.streetinsider.com/Press+Releases/Gandeeva+and+Zymeworks+Use+Cryo-EM+to+Accelerate+Antibody+Drug+Discovery/26663076.html Thu, 18 Jun 2026 08:00:00 -0400 A.50216943 O.02586910 O.56599086 ZYME http://www.streetinsider.com/Press+Releases/Gandeeva+and+Zymeworks+Use+Cryo-EM+to+Accelerate+Antibody+Drug+Discovery/26663076.html <div class="xn-content"> <p><i><location value="LU/ca.bc.vancvr" idsrc="xmltag.org" >Vancouver</location>-based biotech companies <span value="ACORN:5021694305" idsrc="xmltag.org" >Gandeeva Therapeutics</span> and <span value="NASDAQ-NMS:ZYME" idsrc="xmltag.org" >Zymeworks</span> have partnered to generate cryo-EM–based structural data to augment antibody drug discovery.</i></p><p><span class="legendSpanClass"><location value="LU/ca.bc.vancvr" idsrc="xmltag.org" >VANCOUVER, BC</location></span>, <span class="legendSpanClass"><chron>June 18, 2026</chron></span> /PRNewswire/ - <span value="ACORN:5021694305" idsrc="xmltag.org" >Gandeeva Therapeutics, Inc.</span>, a biotech at the forefront of cryo-electron microscopy (cryo-EM)<i>–</i>driven drug design, and <span value="NASDAQ-NMS:ZYME" idsrc="xmltag.org" >Zymeworks Inc.</span> (Nasdaq: ZYME), a global biotechnology company, have partnered to visualize structures of antibody-antigen interfaces at high resolution.</p><p>While cryo-EM is now used routinely to determine structures of antibody complexes formed with compact and well-folded antigens, mapping antibody epitope footprints http://www.streetinsider.com/Press+Releases/Gandeeva+and+Zymeworks+Use+Cryo-EM+to+Accelerate+Antibody+Drug+Discovery/26663076.html Thu, 18 Jun 2026 08:00:00 -0400 A.50216943 O.02586910 O.56599086 ZYME http://www.streetinsider.com/Press+Releases/Gandeeva+and+Zymeworks+Use+Cryo-EM+to+Accelerate+Antibody+Drug+Discovery/26663076.html <div class="xn-content"> <p><i><location value="LU/ca.bc.vancvr" idsrc="xmltag.org" >Vancouver</location>-based biotech companies <span value="ACORN:5021694305" idsrc="xmltag.org" >Gandeeva Therapeutics</span> and <span value="NASDAQ-NMS:ZYME" idsrc="xmltag.org" >Zymeworks</span> have partnered to generate cryo-EM–based structural data to augment antibody drug discovery.</i></p><p><span class="legendSpanClass"><location value="LU/ca.bc.vancvr" idsrc="xmltag.org" >VANCOUVER, BC</location></span>, <span class="legendSpanClass"><chron>June 18, 2026</chron></span> /PRNewswire/ - <span value="ACORN:5021694305" idsrc="xmltag.org" >Gandeeva Therapeutics, Inc.</span>, a biotech at the forefront of cryo-electron microscopy (cryo-EM)<i>–</i>driven drug design, and <span value="NASDAQ-NMS:ZYME" idsrc="xmltag.org" >Zymeworks Inc.</span> (Nasdaq: ZYME), a global biotechnology company, have partnered to visualize structures of antibody-antigen interfaces at high resolution.</p><p>While cryo-EM is now used routinely to determine structures of antibody complexes formed with compact and well-folded antigens, mapping antibody epitope footprints http://www.streetinsider.com/Press+Releases/Gandeeva+and+Zymeworks+Use+Cryo-EM+to+Accelerate+Antibody+Drug+Discovery/26663076.html Thu, 18 Jun 2026 08:00:00 -0400 A.50216943 O.02586910 O.56599086 ZYME http://www.streetinsider.com/PRNewswire/Gandeeva+and+Zymeworks+Use+Cryo-EM+to+Accelerate+Antibody+Drug+Discovery/26663076.html <div class="xn-content"> <p><i><location value="LU/ca.bc.vancvr" idsrc="xmltag.org" >Vancouver</location>-based biotech companies <span value="ACORN:5021694305" idsrc="xmltag.org" >Gandeeva Therapeutics</span> and <span value="NASDAQ-NMS:ZYME" idsrc="xmltag.org" >Zymeworks</span> have partnered to generate cryo-EM–based structural data to augment antibody drug discovery.</i></p><p><span class="legendSpanClass"><location value="LU/ca.bc.vancvr" idsrc="xmltag.org" >VANCOUVER, BC</location></span>, <span class="legendSpanClass"><chron>June 18, 2026</chron></span> /PRNewswire/ - <span value="ACORN:5021694305" idsrc="xmltag.org" >Gandeeva Therapeutics, Inc.</span>, a biotech at the forefront of cryo-electron microscopy (cryo-EM)<i>–</i>driven drug design, and <span value="NASDAQ-NMS:ZYME" idsrc="xmltag.org" >Zymeworks Inc.</span> (Nasdaq: ZYME), a global biotechnology company, have partnered to visualize structures of antibody-antigen interfaces at high resolution.</p><p>While cryo-EM is now used routinely to determine structures of antibody complexes formed with compact and well-folded antigens, mapping antibody epitope footprints http://www.streetinsider.com/PRNewswire/Gandeeva+and+Zymeworks+Use+Cryo-EM+to+Accelerate+Antibody+Drug+Discovery/26663076.html Thu, 18 Jun 2026 08:00:00 -0400 A.50216943 O.02586910 O.56599086 ZYME http://www.streetinsider.com/PRNewswire/Gandeeva+and+Zymeworks+Use+Cryo-EM+to+Accelerate+Antibody+Drug+Discovery/26663076.html <div class="xn-content"> <p><i><location value="LU/ca.bc.vancvr" idsrc="xmltag.org" >Vancouver</location>-based biotech companies <span value="ACORN:5021694305" idsrc="xmltag.org" >Gandeeva Therapeutics</span> and <span value="NASDAQ-NMS:ZYME" idsrc="xmltag.org" >Zymeworks</span> have partnered to generate cryo-EM–based structural data to augment antibody drug discovery.</i></p><p><span class="legendSpanClass"><location value="LU/ca.bc.vancvr" idsrc="xmltag.org" >VANCOUVER, BC</location></span>, <span class="legendSpanClass"><chron>June 18, 2026</chron></span> /PRNewswire/ - <span value="ACORN:5021694305" idsrc="xmltag.org" >Gandeeva Therapeutics, Inc.</span>, a biotech at the forefront of cryo-electron microscopy (cryo-EM)<i>–</i>driven drug design, and <span value="NASDAQ-NMS:ZYME" idsrc="xmltag.org" >Zymeworks Inc.</span> (Nasdaq: ZYME), a global biotechnology company, have partnered to visualize structures of antibody-antigen interfaces at high resolution.</p><p>While cryo-EM is now used routinely to determine structures of antibody complexes formed with compact and well-folded antigens, mapping antibody epitope footprints http://www.streetinsider.com/PRNewswire/Gandeeva+and+Zymeworks+Use+Cryo-EM+to+Accelerate+Antibody+Drug+Discovery/26663076.html Thu, 18 Jun 2026 08:00:00 -0400 A.50216943 O.02586910 O.56599086 ZYME http://www.streetinsider.com/PRNewswire/Gandeeva+and+Zymeworks+Use+Cryo-EM+to+Accelerate+Antibody+Drug+Discovery/26663076.html <div class="xn-content"> <p><i><location value="LU/ca.bc.vancvr" idsrc="xmltag.org" >Vancouver</location>-based biotech companies <span value="ACORN:5021694305" idsrc="xmltag.org" >Gandeeva Therapeutics</span> and <span value="NASDAQ-NMS:ZYME" idsrc="xmltag.org" >Zymeworks</span> have partnered to generate cryo-EM–based structural data to augment antibody drug discovery.</i></p><p><span class="legendSpanClass"><location value="LU/ca.bc.vancvr" idsrc="xmltag.org" >VANCOUVER, BC</location></span>, <span class="legendSpanClass"><chron>June 18, 2026</chron></span> /PRNewswire/ - <span value="ACORN:5021694305" idsrc="xmltag.org" >Gandeeva Therapeutics, Inc.</span>, a biotech at the forefront of cryo-electron microscopy (cryo-EM)<i>–</i>driven drug design, and <span value="NASDAQ-NMS:ZYME" idsrc="xmltag.org" >Zymeworks Inc.</span> (Nasdaq: ZYME), a global biotechnology company, have partnered to visualize structures of antibody-antigen interfaces at high resolution.</p><p>While cryo-EM is now used routinely to determine structures of antibody complexes formed with compact and well-folded antigens, mapping antibody epitope footprints http://www.streetinsider.com/PRNewswire/Gandeeva+and+Zymeworks+Use+Cryo-EM+to+Accelerate+Antibody+Drug+Discovery/26663076.html Thu, 18 Jun 2026 08:00:00 -0400 A.50216943 O.02586910 O.56599086 ZYME http://www.streetinsider.com/PRNewswire/Gandeeva+and+Zymeworks+Use+Cryo-EM+to+Accelerate+Antibody+Drug+Discovery/26663076.html <div class="xn-content"> <p><i><location value="LU/ca.bc.vancvr" idsrc="xmltag.org" >Vancouver</location>-based biotech companies <span value="ACORN:5021694305" idsrc="xmltag.org" >Gandeeva Therapeutics</span> and <span value="NASDAQ-NMS:ZYME" idsrc="xmltag.org" >Zymeworks</span> have partnered to generate cryo-EM–based structural data to augment antibody drug discovery.</i></p><p><span class="legendSpanClass"><location value="LU/ca.bc.vancvr" idsrc="xmltag.org" >VANCOUVER, BC</location></span>, <span class="legendSpanClass"><chron>June 18, 2026</chron></span> /PRNewswire/ - <span value="ACORN:5021694305" idsrc="xmltag.org" >Gandeeva Therapeutics, Inc.</span>, a biotech at the forefront of cryo-electron microscopy (cryo-EM)<i>–</i>driven drug design, and <span value="NASDAQ-NMS:ZYME" idsrc="xmltag.org" >Zymeworks Inc.</span> (Nasdaq: ZYME), a global biotechnology company, have partnered to visualize structures of antibody-antigen interfaces at high resolution.</p><p>While cryo-EM is now used routinely to determine structures of antibody complexes formed with compact and well-folded antigens, mapping antibody epitope footprints http://www.streetinsider.com/PRNewswire/Gandeeva+and+Zymeworks+Use+Cryo-EM+to+Accelerate+Antibody+Drug+Discovery/26663076.html Thu, 18 Jun 2026 08:00:00 -0400 A.50216943 O.02586910 O.56599086 ZYME http://www.streetinsider.com/Analyst+Comments/Zymeworks+%28ZYME%29+Reiterated+at+Market+Outperform+by+Citizens+on+ZW191+Efficacy+Data/26649616.html <p>Citizens analyst Reni Benjamin reiterated a Market Outperform rating and $32.00 price target on Zymeworks (NASDAQ: ZYME).</p><p>The analyst commented, "We reiterate our Market Outperform rating for Zymeworks (ZYME) and our price target of $32 based on a discounted EPS and revenue multiple analysis. Recently at ESMO-GYN, Zymeworks presented an updated efficacy analysis of ZW191 (FRα TOPO1i ADC) stratified by FRα expression. The new analysis shows a clean expression-response relationship with FRα-positive patients responding better than FRα-negative PROC. With zanidatamab on track for a potential approval in 1L GEA, ZW191 and ZW251 (GPC3 TOPO1i ADC) advancing in early clinical development, a http://www.streetinsider.com/Analyst+Comments/Zymeworks+%28ZYME%29+Reiterated+at+Market+Outperform+by+Citizens+on+ZW191+Efficacy+Data/26649616.html Tue, 16 Jun 2026 05:25:02 -0400 ZYME http://www.streetinsider.com/FDA/Zymeworks+reports+phase+1+data+for+cancer+drug+ZW191/26642963.html <p>Zymeworks Inc. (NASDAQ: ZYME) presented clinical data for its experimental cancer treatment ZW191 at the European Society for Medical Oncology Gynaecological Cancers Congress 2026. The folate receptor alpha-targeting antibody-drug conjugate showed activity in platinum-resistant ovarian cancer patients.</p> <p>In the phase 1 study, ZW191 achieved a confirmed objective response rate of 78.6% in patients with FRα-positive platinum-resistant ovarian cancer and 47.4% in FRα-negative patients across all dose levels studied. The overall confirmed response rate in platinum-resistant ovarian cancer patients was 58.8% across all doses and 65.2% in the 6.4-9.6 mg/kg dose range.</p> <p>For endometrial cancer patients with FRα-negative tumors, ZW191 demonstrated a confirmed http://www.streetinsider.com/FDA/Zymeworks+reports+phase+1+data+for+cancer+drug+ZW191/26642963.html Sun, 14 Jun 2026 18:05:13 -0400 ZYME http://www.streetinsider.com/Press+Releases/Zymeworks+Presents+New+Phase+1+Data+for+Folate+Receptor+Alpha-Targeting+ADC+ZW191+at+ESMO+Gynaecological+Cancers+Congress+2026/26642962.html <ul type="disc"><li style="margin-bottom:8pt;"><em>ZW191 demonstrates compelling anti-tumor activity in platinum-resistant ovarian cancer patients regardless of FRα expression level</em></li><li style="margin-bottom:8pt;"><em>Confirmed objective response rate (cORR) of 78.6% in FRα-positive (≥75% at PS2+) platinum-resistant ovarian cancer patients and 47.4% in FRα-negative patients (&lt;75% at PS2+) across all dose levels studied</em></li><li style="margin-bottom:8pt;"><em>Median duration of response was not reached at the time of data cutoff, and median progression-free survival was 7.6 months across ovarian and endometrial cancer cohorts</em></li><li style="margin-bottom:8pt;"><em>Patient recruitment in dose optimization cohorts completed, with favorable tolerability profile and broad therapeutic window supporting continued clinical development</em></li></ul> <p>VANCOUVER, British Columbia, June 14, 2026 http://www.streetinsider.com/Press+Releases/Zymeworks+Presents+New+Phase+1+Data+for+Folate+Receptor+Alpha-Targeting+ADC+ZW191+at+ESMO+Gynaecological+Cancers+Congress+2026/26642962.html Sun, 14 Jun 2026 18:05:00 -0400 ZYME http://www.streetinsider.com/Globe+Newswire/Zymeworks+Presents+New+Phase+1+Data+for+Folate+Receptor+Alpha-Targeting+ADC+ZW191+at+ESMO+Gynaecological+Cancers+Congress+2026/26642962.html <ul type="disc"><li style="margin-bottom:8pt;"><em>ZW191 demonstrates compelling anti-tumor activity in platinum-resistant ovarian cancer patients regardless of FRα expression level</em></li><li style="margin-bottom:8pt;"><em>Confirmed objective response rate (cORR) of 78.6% in FRα-positive (≥75% at PS2+) platinum-resistant ovarian cancer patients and 47.4% in FRα-negative patients (&lt;75% at PS2+) across all dose levels studied</em></li><li style="margin-bottom:8pt;"><em>Median duration of response was not reached at the time of data cutoff, and median progression-free survival was 7.6 months across ovarian and endometrial cancer cohorts</em></li><li style="margin-bottom:8pt;"><em>Patient recruitment in dose optimization cohorts completed, with favorable tolerability profile and broad therapeutic window supporting continued clinical development</em></li></ul> <p>VANCOUVER, British Columbia, June 14, 2026 http://www.streetinsider.com/Globe+Newswire/Zymeworks+Presents+New+Phase+1+Data+for+Folate+Receptor+Alpha-Targeting+ADC+ZW191+at+ESMO+Gynaecological+Cancers+Congress+2026/26642962.html Sun, 14 Jun 2026 18:05:00 -0400 ZYME http://www.streetinsider.com/New+Coverage/Truist+Securities+Assumes+Zymeworks+%28ZYME%29+at+Buy/26619816.html <p>Truist Securities analyst Gregory Renza assumes coverage on Zymeworks (NASDAQ: ZYME) with a Buy rating and a price target of $28.00.</p><p>The analyst comments "We assume coverage of ZYME with an unchanged Buy rating at a $28 PT (from $40). We look to ZYME as a balanced sector play, leveraging an operational royalty platform, with a robust oncology+ pipeline as a sweetener for LT growth prospects. Current royalty revenues via Ziihera could see additional legs up for inflows via approval in 1L GEA - with the August 25th PDUFA - and opportunity in additional HER2+ solid tumors including BC. We see http://www.streetinsider.com/New+Coverage/Truist+Securities+Assumes+Zymeworks+%28ZYME%29+at+Buy/26619816.html Tue, 09 Jun 2026 06:08:21 -0400 ZYME http://www.streetinsider.com/Analyst+Comments/Truist+Securities+Assumes+Zymeworks+%28ZYME%29+at+Buy/26619816.html <p>Truist Securities analyst Gregory Renza assumes coverage on Zymeworks (NASDAQ: ZYME) with a Buy rating and a price target of $28.00.</p><p>The analyst comments "We assume coverage of ZYME with an unchanged Buy rating at a $28 PT (from $40). We look to ZYME as a balanced sector play, leveraging an operational royalty platform, with a robust oncology+ pipeline as a sweetener for LT growth prospects. Current royalty revenues via Ziihera could see additional legs up for inflows via approval in 1L GEA - with the August 25th PDUFA - and opportunity in additional HER2+ solid tumors including BC. We see http://www.streetinsider.com/Analyst+Comments/Truist+Securities+Assumes+Zymeworks+%28ZYME%29+at+Buy/26619816.html Tue, 09 Jun 2026 06:08:21 -0400 ZYME http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+Zymeworks+%28ZYME%29/26595112.html <p>H.C. Wainwright analyst Andrew Berens reiterated a Buy rating and $46.00 price target on Zymeworks (NASDAQ: ZYME).</p><p>The analyst commented: "Zymeworks' partner, Jazz Pharmaceuticals (JAZZ: Under Review), recently announced that the results from the Phase 3 HERIZON-GEA-01 trial, which is evaluating Ziihera (zanidatamab) plus chemotherapy, with or without the PD-1 inhibitor Tevimbra (tislelizumab), for the treatment of 1L HER2+ locally advanced or metastatic gastroesophageal cancers, were published in NEJM. Consistent with data previously presented at ASCO GI 2026, both Ziihera-containing regimens delivered highly statistically significant and clinically meaningful improvements in progression-free survival (PFS) compared with Herceptin (trastuzumab) plus chemotherapy. Median PFS http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+Zymeworks+%28ZYME%29/26595112.html Wed, 03 Jun 2026 06:52:12 -0400 ZYME http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Zymeworks+Inc.++++++++++++For%3A+May+13++Filed+by%3A+Schneider+Paul+R/26507494.html si-local-file:///var/storage/secattach/20260515/26507494.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Zymeworks+Inc.++++++++++++For%3A+May+13++Filed+by%3A+Schneider+Paul+R/26507494.html Fri, 15 May 2026 17:00:00 -0400 O.02586910 ZYME http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Zymeworks+Inc.++++++++++++For%3A+May+13++Filed+by%3A+Schneider+Paul+R/26507494.html si-local-file:///var/storage/secattach/20260515/26507494.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Zymeworks+Inc.++++++++++++For%3A+May+13++Filed+by%3A+Schneider+Paul+R/26507494.html Fri, 15 May 2026 17:00:00 -0400 O.02586910 ZYME http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Zymeworks+Inc.++++++++++++For%3A+May+13++Filed+by%3A+Schneider+Paul+R/26507377.html si-local-file:///var/storage/secattach/20260515/26507377.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Zymeworks+Inc.++++++++++++For%3A+May+13++Filed+by%3A+Schneider+Paul+R/26507377.html Fri, 15 May 2026 16:55:00 -0400 O.02586910 ZYME http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Zymeworks+Inc.++++++++++++For%3A+May+13++Filed+by%3A+Schneider+Paul+R/26507377.html si-local-file:///var/storage/secattach/20260515/26507377.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Zymeworks+Inc.++++++++++++For%3A+May+13++Filed+by%3A+Schneider+Paul+R/26507377.html Fri, 15 May 2026 16:55:00 -0400 O.02586910 ZYME http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Zymeworks+Inc.+++++++++++++++++++++++++Filed+by%3A+Rubric+Capital+Management+LP/26505486.html si-local-file:///var/storage/secattach/20260515/26505486.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Zymeworks+Inc.+++++++++++++++++++++++++Filed+by%3A+Rubric+Capital+Management+LP/26505486.html Fri, 15 May 2026 16:15:00 -0400 O.02586910 ZYME http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Zymeworks+Inc.+++++++++++++++++++++++++Filed+by%3A+Rubric+Capital+Management+LP/26505486.html si-local-file:///var/storage/secattach/20260515/26505486.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Zymeworks+Inc.+++++++++++++++++++++++++Filed+by%3A+Rubric+Capital+Management+LP/26505486.html Fri, 15 May 2026 16:15:00 -0400 O.02586910 ZYME http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Zymeworks+Inc.++++++++++++For%3A+May+14/26495656.html si-local-file:///var/storage/secattach/20260514/26495656.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Zymeworks+Inc.++++++++++++For%3A+May+14/26495656.html Thu, 14 May 2026 16:30:00 -0400 O.02586910 ZYME http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Zymeworks+Inc.++++++++++++For%3A+May+14/26495656.html si-local-file:///var/storage/secattach/20260514/26495656.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Zymeworks+Inc.++++++++++++For%3A+May+14/26495656.html Thu, 14 May 2026 16:30:00 -0400 O.02586910 ZYME http://www.streetinsider.com/Stock+Buybacks/Zymeworks+authorizes+%24125+million+share+repurchase+program/26494545.html <p>Zymeworks Inc. (NASDAQ: ZYME) announced that its board of directors authorized a new share repurchase program allowing the company to buy back up to $125 million of its outstanding common stock. The biotechnology company also terminated its existing 2025 share repurchase program, under which it repurchased 4.2 million shares for $102.3 million at an average price of $24.36 per share.</p> <p>The Vancouver-based company had approximately 73 million outstanding common shares as of May 13, 2026, according to the press release statement.</p> <p>"The authorization of this 2026 share repurchase program reflects our continued focus on disciplined capital allocation and long-term value creation," said http://www.streetinsider.com/Stock+Buybacks/Zymeworks+authorizes+%24125+million+share+repurchase+program/26494545.html Thu, 14 May 2026 16:05:14 -0400 ZYME